Non-Ablative Fractional Laser to Facilitate Transdermal Delivery.
The advances in laser technology have led to its rapidly expanding applications in dermatology. This study aims at the novel use of a non-ablative fractional laser to enhance transdermal permeation of diclofenac sodium and sumatriptan succinate. The effects of the laser on skin were characterized visually with dye binding, scanning electron microscopy, pore permeability index, and histology. In vitro transdermal permeation of drugs through laser treated and untreated human dermatomed skin was analyzed over 24 h and quantified by HPLC. Drug transport through untreated skin resulted in transdermal delivery of 72.61 μg/cm2± 50.35 and 22.80 ± 0.64 μg/cm2of diclofenac sodium and sumatriptan succinate, respectively. Laser treatment of skin significantly increased (p < 0.005) delivery of diclofenac sodium to 575.66 ± 207.18 μg/cm2and sumatriptan succinate to 498.32 ± 97.54 μg/cm2. This is a first of its kind study that demonstrates the use of 1410 nm non-ablative fractional laser to enhance transdermal permeation of 2 small molecular weight drugs.
College of Pharmacy, Mercer University, Atlanta, Georgia 30341.
Sindhu S
SS
Ganti
College of Pharmacy, Mercer University, Atlanta, Georgia 30341. Electronic address: banga_ak@mercer.edu.
Ajay K
AK
Banga
D000279:Administration, Cutaneous; D004008:Diclofenac / Q000008:administration & dosage / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D017097:Electric Impedance; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D009924:Organ Culture Techniques; D012869:Skin Absorption / Q000187:drug effects / Q000502:physiology*; D018170:Sumatriptan / Q000008:administration & dosage / Q000378:metabolism*
D004008:Diclofenac; D018170:Sumatriptan
PaloVia; diclofenac sodium; fractional laser; human skin; non-ablative; sumatriptan succinate; transdermal drug delivery